triazoles has been researched along with tavaborole in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (94.74) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Lipner, S; Scher, RK | 1 |
| Fraser, K | 1 |
| Jim, SC; Kircik, LH; Routt, ET; Zeichner, JA | 1 |
| Bhatia, N; Friedlander, SF; Gupta, AK; Kircik, L; Rosen, T; Stein Gold, L; Zirwas, MJ | 1 |
| Hussar, DA | 1 |
| Chanda, S; Coronado, D; Merchant, T; Vlahovic, TC; Zane, LT | 1 |
| Dorval, E; Grace, Y; Machin, JD; Poulakos, M | 1 |
| Rosen, T; Stein Gold, LF | 3 |
| Chanda, S; Coronado, D; Del Rosso, J; Zane, LT | 1 |
| Lagrew, JP | 1 |
| Elewski, BE | 1 |
| Koski, R; Maki, K; Nybo, SE; Saunders, J | 1 |
| Adigun, CG; Gellings Lowe, N; Hall, SB; Joseph, WS; Rich, P; Vlahovic, TC; Zane, LT | 1 |
| Ilie, C; Pollak, RA | 1 |
| Lipner, SR; Scher, RK | 1 |
| Ko, D; Lipner, SR | 1 |
| Lipner, SR; Wang, Y | 1 |
7 review(s) available for triazoles and tavaborole
| Article | Year |
|---|---|
What is new in fungal pharmacotherapeutics?
Topics: Allylamine; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Education, Medical, Continuing; Humans; Imidazoles; Itraconazole; Onychomycosis; Tinea Pedis; Triazoles | 2014 |
Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape.
Topics: Anti-Infective Agents, Local; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Onychomycosis; Pharmaceutical Solutions; Treatment Outcome; Triazoles | 2015 |
New drugs 2015, part 3.
Topics: Acids, Carbocyclic; Benzoxazines; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cephalosporins; Cyclopentanes; Drug Approval; Drug Combinations; Drug Therapy; Glucagon-Like Peptides; Guanidines; Humans; Imidazoles; Immunoglobulin Fc Fragments; Interferon-beta; Isoquinolines; Penicillanic Acid; Polyethylene Glycols; Pyridines; Quinuclidines; Recombinant Fusion Proteins; Tazobactam; Triazoles; United States; United States Food and Drug Administration | 2015 |
Efinaconazole and Tavaborole.
Topics: Administration, Topical; Animals; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Foot Dermatoses; Humans; Microbial Sensitivity Tests; Onychomycosis; Triazoles | 2017 |
Antifungal agents for onychomycosis: new treatment strategies to improve safety.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Chemical and Drug Induced Liver Injury; Ciclopirox; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2016 |
Tavaborole, Efinaconazole, and Luliconazole: Three New Antimycotic Agents for the Treatment of Dermatophytic Fungi.
Topics: Administration, Topical; Animals; Antifungal Agents; Arthrodermataceae; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Dermatomycoses; Humans; Imidazoles; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2017 |
Onychomycosis: Treatment and prevention of recurrence.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Fluconazole; Humans; Itraconazole; Laser Therapy; Nanoparticles; Onychomycosis; Photochemotherapy; Plasma Gases; Prognosis; Pulse Therapy, Drug; Risk Factors; Secondary Prevention; Severity of Illness Index; Terbinafine; Triazoles | 2019 |
2 trial(s) available for triazoles and tavaborole
| Article | Year |
|---|---|
A financial perspective on the topical treatment of onychomycosis.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Follow-Up Studies; Foot Dermatoses; Humans; Male; Onychomycosis; Risk Assessment; Treatment Outcome; Triazoles | 2016 |
Long-Term Follow-up of Onychomycosis Patients Treated With Efinaconazole
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Onychomycosis; Treatment Outcome; Triazoles; Young Adult | 2017 |
10 other study(ies) available for triazoles and tavaborole
| Article | Year |
|---|---|
Onychomycosis: current and future therapies.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Debridement; Foot Dermatoses; Hand Dermatoses; Humans; Laser Therapy; Morpholines; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Triazoles | 2014 |
72nd annual meeting of the American Academy of Dermatology.
Topics: Antifungal Agents; Attention Deficit Disorder with Hyperactivity; Boron Compounds; Botulinum Toxins, Type A; Bridged Bicyclo Compounds, Heterocyclic; Brimonidine Tartrate; Depression; Dermatitis, Atopic; Food Hypersensitivity; Humans; Immunologic Factors; Ivermectin; Phosphodiesterase Inhibitors; Phototherapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinoxalines; Skin Diseases; Societies, Medical; Thalidomide; Triazoles; United States | 2014 |
Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole.
Topics: Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Nails; Onychomycosis; Triazoles | 2016 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Fluconazole; Foot Dermatoses; Humans; Itraconazole; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles; United States | 2016 |
Introduction.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Foot Dermatoses; Humans; Naphthalenes; Onychomycosis; Pyridones; Terbinafine; Treatment Outcome; Triazoles | 2016 |
Using Topical Antifungal Medications: Instructions for patients.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Drug Administration Schedule; Foot Dermatoses; Humans; Onychomycosis; Pyridones; Triazoles | 2016 |
Response to "A financial perspective on the topical treatment of onychomycosis".
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cost-Benefit Analysis; Drug Costs; Female; Foot Dermatoses; Humans; Male; Onychomycosis; Sensitivity and Specificity; Severity of Illness Index; Triazoles | 2016 |
Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice.
Topics: Administration, Cutaneous; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Onychomycosis; Pyridones; Research Design; Treatment Outcome; Triazoles; United States | 2017 |
Optimizing topical therapy for onychomycosis: the importance of patient education.
Topics: Administration, Topical; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Humans; Medication Adherence; Onychomycosis; Patient Education as Topic; Triazoles | 2018 |
Retrospective analysis of adverse events with topical onychomycosis medications reported to the United States Food and Drug Administration.
Topics: Administration, Topical; Adverse Drug Reaction Reporting Systems; Antifungal Agents; Boron Compounds; Bridged Bicyclo Compounds, Heterocyclic; Ciclopirox; Erythema; Humans; Nails; Onychomycosis; Pigmentation; Retrospective Studies; Solutions; Treatment Failure; Triazoles; United States; United States Food and Drug Administration | 2020 |